• Lanabecestat (AZD3293): Protocol Innovations in Alzheimer’s

  2026-05-26

  Lanabecestat (AZD3293) enables precise, synaptic-sparing BACE1 inhibition for Alzheimer’s disease research, supporting nuanced control of amyloid-beta production while preserving neuronal function. This guide details optimized protocols, experimental use-cases, and troubleshooting strategies uniquely enabled by its nanomolar potency and brain penetrance.

• ZCL278: Selective Cdc42 Inhibitor for Advanced Cell Motility

  2026-05-26

  ZCL278 is a benchmark selective Cdc42 inhibitor, enabling precise suppression of cell motility and neuronal branching for cancer, neurobiology, and fibrosis research. Discover how optimized workflows, troubleshooting strategies, and real-world protocol parameters empower researchers to dissect Cdc42 signaling with confidence.

• Toremifene: Selective Estrogen-Receptor Modulator in Prostat

  2026-05-25

  Toremifene, a second-generation selective estrogen-receptor modulator, empowers researchers to dissect hormone-driven and metastatic processes in prostate cancer models. This article delivers actionable protocols, data-driven insights, and troubleshooting strategies—bridging cutting-edge findings on calcium signaling and bone metastasis with practical laboratory applications.

• Zoledronic Acid Applications: Protocols in Cancer and Bone R

  2026-05-25

  Zoledronic Acid stands out as a potent nitrogen-containing bisphosphonate, offering robust anti-proliferative and pro-apoptotic effects in cancer and bone disease models. This article delivers stepwise protocols, advanced workflow insights, and troubleshooting strategies, empowering researchers to leverage Zoledronic Acid for high-impact, reproducible results.

• Elobixibat Hydrate: Systems Pharmacology and Translational I

  2026-05-24

  Explore the multidimensional systems pharmacology of Elobixibat hydrate, a leading ileal bile acid transporter inhibitor. This article reveals advanced experimental insights and practical assay implications, setting a new benchmark for GI and metabolic research.

• Microbiota–Tryptophan–AhR Axis in UC: Mechanistic Insights f

  2026-05-23

  Li et al. demonstrate that Huangqin decoction (HQD) promotes intestinal repair in ulcerative colitis by orchestrating gut microbiota-driven tryptophan metabolism and activating the aryl hydrocarbon receptor (AhR) pathway, leading to enhanced intestinal stem cell differentiation. This study delineates a novel mechanistic axis linking microbial metabolites and mucosal regeneration, providing a framework for targeted AhR signaling modulation in gastrointestinal disease.

• 4-Hydroxytamoxifen: Technical Guidance for Research Workflow

  2026-05-22

  4-Hydroxytamoxifen is a high-purity estrogen receptor modulator designed for research applications such as breast and prostate cancer models, apoptosis assays, and cardiac myocyte studies. It is suitable only for DMSO-based protocols and requires strict storage and handling to maintain reproducibility. This reagent is not recommended where ethanol or aqueous solubility is essential.

• Lactylation-Driven NSUN2 m5C Modification Fuels PDAC Nerve I

  2026-05-22

  This study reveals how lactate-induced lysine lactylation of the RNA methyltransferase NSUN2 at K692 enhances its stability and drives m5C RNA modifications that promote perineural invasion in pancreatic ductal adenocarcinoma (PDAC). These findings delineate a novel metabolic-epitranscriptomic axis underlying PDAC aggressiveness and suggest actionable targets for limiting neural invasion.

• Applied (S)-(+)-Ibuprofen: COX Inhibitor Workflows & Insight

  2026-05-21

  (S)-(+)-Ibuprofen stands out as a benchmark COX inhibitor for precise inflammation and pain mechanism research, offering enhanced selectivity and reproducibility across in vitro and in vivo models. This article dissects experimental protocols, troubleshooting strategies, and practical innovations to help researchers leverage APExBIO's high-purity product for next-generation nonsteroidal anti-inflammatory drug research.

• Protease Inhibitor Cocktail (100X H₂O, EDTA Plus): Precision

  2026-05-21

  Explore how the Protease Inhibitor Cocktail (100X H₂O, EDTA Plus) elevates protein stability in advanced lipid droplet research. This article details its mechanistic advantages and provides new guidance for achieving reproducible DFCP1-ATGL interaction studies.

• MDV3100 (Enzalutamide): Mechanistic Insight and Translationa

  2026-05-20

  This thought-leadership article advances the prostate cancer research conversation by dissecting how MDV3100 (Enzalutamide) enables rigorous mechanistic studies of androgen receptor (AR) signaling, apoptosis induction, and therapeutic resistance, anchored by the latest insights into glycosaminoglycan biosynthesis and UGDH phosphorylation. Targeted at translational researchers, it offers a strategic synthesis of biological rationale, experimental guidance, and future outlook, with actionable protocol recommendations and an explicit bridge to resistance mechanisms recently characterized in peer-reviewed literature.

• Molnupiravir Suppresses Bourbon Virus Pathology in Mice

  2026-05-20

  This study provides the first in vivo evidence that molnupiravir, an orally available nucleoside analogue, significantly inhibits Bourbon virus (BRBV) replication and disease progression in a mouse model. The findings establish a foundation for evaluating similar broad-spectrum antivirals against emerging tick-borne RNA viruses lacking approved treatments.

• IR-1061: Redefining Deep Tissue NIR Imaging for Translationa

  2026-05-19

  This article explores how IR-1061, a next-generation near infrared fluorescent dye from APExBIO, is transforming the landscape of in vivo deep tissue imaging. Blending mechanistic insight with strategic guidance, it navigates the challenges of optical imaging in translational research—integrating recent advances in nanoparticle encapsulation, practical protocol recommendations, and a critical analysis of current and future directions.

• Axitinib (AG 013736): Precision Profiling in Angiogenesis As

  2026-05-19

  Uncover how Axitinib (AG 013736) enables precision angiogenesis inhibition in advanced cancer biology research. This article integrates nuanced assay guidance, mechanistic depth, and insights from recent in vitro drug response innovations.

• Enhanced In Vitro Drug Response Evaluation in Cancer Researc

  2026-05-18

  Schwartz (2022) introduces advanced in vitro methodologies to distinguish between drug-induced proliferative arrest and cell death in cancer models. This work clarifies common pitfalls in interpreting anti-cancer drug efficacy and offers practical improvements for experimental design, with implications for precise mechanistic studies involving tools such as potassium ionophores.

453 records 17/31 page Previous Next First page 上5页 1617181920 下5页 Last page